Literature DB >> 20439824

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.

Shaun M Eack1, Gerard E Hogarty, Raymond Y Cho, Konasale M R Prasad, Deborah P Greenwald, Susan S Hogarty, Matcheri S Keshavan.   

Abstract

CONTEXT: Cognitive rehabilitation has shown efficacy in improving cognition in patients with schizophrenia but the underlying neurobiologic changes that occur during these treatments and support cognitive improvement are not well known.
OBJECTIVE: To examine differential changes in brain morphology in early course schizophrenia during cognitive rehabilitation vs supportive therapy.
DESIGN: Randomized controlled trial.
SETTING: An outpatient research clinic at a university-based medical center that provides comprehensive care services for patients with severe mental illness. PATIENTS: A total of 53 symptomatically stable but cognitively disabled outpatients in the early course of schizophrenia or schizoaffective disorder.
INTERVENTIONS: A 2-year trial with annual structural magnetic resonance imaging and cognitive assessments. Cognitive enhancement therapy is an integrated approach to the remediation of cognitive impairment in schizophrenia that uses computer-assisted neurocognitive training and group-based social-cognitive exercises. Enriched supportive therapy is an illness management approach that provides psychoeducation and teaches applied coping strategies. MAIN OUTCOME MEASURES: Broad areas of frontal and temporal gray matter change were analyzed with longitudinal, voxel-based morphometry methods using mixed-effects models followed by volumetric analyses of regions that demonstrated significant differential changes between treatment groups.
RESULTS: Patients who received cognitive enhancement therapy demonstrated significantly greater preservation of gray matter volume over 2 years in the left hippocampus, parahippocampal gyrus, and fusiform gyrus, and significantly greater gray matter increases in the left amygdala (all corrected P < .04) compared with those who received enriched supportive therapy. Less gray matter loss in the left parahippocampal and fusiform gyrus and greater gray matter increases in the left amygdala were significantly related to improved cognition and mediated the beneficial cognitive effects of cognitive enhancement therapy.
CONCLUSION: Cognitive enhancement therapy may offer neurobiologic protective and enhancing effects in early schizophrenia that are associated with improved long-term cognitive outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20439824      PMCID: PMC3741671          DOI: 10.1001/archgenpsychiatry.2010.63

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  51 in total

1.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

Review 2.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

Authors:  Ralitza Gueorguieva; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2004-03

3.  The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia.

Authors:  R W Buchanan; D W Heinrichs
Journal:  Psychiatry Res       Date:  1989-03       Impact factor: 3.222

4.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.

Authors:  R M Baron; D A Kenny
Journal:  J Pers Soc Psychol       Date:  1986-12

Review 5.  Social cognition in schizophrenia.

Authors:  D L Penn; P W Corrigan; R P Bentall; J M Racenstein; L Newman
Journal:  Psychol Bull       Date:  1997-01       Impact factor: 17.737

Review 6.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

Review 7.  The relationship between brain structure and neurocognition in schizophrenia: a selective review.

Authors:  Elena Antonova; Tonmoy Sharma; Robin Morris; Veena Kumari
Journal:  Schizophr Res       Date:  2004-10-01       Impact factor: 4.939

Review 8.  Implications for the neural basis of social cognition for the study of schizophrenia.

Authors:  Amy E Pinkham; David L Penn; Diana O Perkins; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

9.  Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

Authors:  Gerard E Hogarty; Samuel Flesher; Richard Ulrich; Mary Carter; Deborah Greenwald; Michael Pogue-Geile; Matcheri Kechavan; Susan Cooley; Ann Louise DiBarry; Ann Garrett; Haranath Parepally; Rebecca Zoretich
Journal:  Arch Gen Psychiatry       Date:  2004-09

10.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence.

Authors:  D R Weinberger; K F Berman; R F Zec
Journal:  Arch Gen Psychiatry       Date:  1986-02
View more
  119 in total

1.  Will there be a role for neuroimaging in clinical psychiatry?

Authors:  Glenda M Macqueen
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

2.  Cognitive remediation therapy needs funding.

Authors:  Til Wykes
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 3.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 4.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

5.  Brief report: is cognitive rehabilitation needed in verbal adults with autism? Insights from initial enrollment in a trial of cognitive enhancement therapy.

Authors:  Shaun M Eack; Amber L Bahorik; Susan S Hogarty; Deborah P Greenwald; Maralee Y Litschge; Carla A Mazefsky; Nancy J Minshew
Journal:  J Autism Dev Disord       Date:  2013-09

6.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

Review 7.  Neuroimaging for psychotherapy research: current trends.

Authors:  Carol P Weingarten; Timothy J Strauman
Journal:  Psychother Res       Date:  2014-02-17

Review 8.  Social impairment in schizophrenia: new approaches for treating a persistent problem.

Authors:  David Dodell-Feder; Laura M Tully; Christine I Hooker
Journal:  Curr Opin Psychiatry       Date:  2015-05       Impact factor: 4.741

9.  Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus.

Authors:  Evelin L Schaeffer; Fabiana G Cerulli; Hélio O X Souza; Sergio Catanozi; Wagner F Gattaz
Journal:  J Neural Transm (Vienna)       Date:  2014-02-20       Impact factor: 3.575

10.  Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches.

Authors:  Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell
Journal:  Am J Psychiatr Rehabil       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.